{"id":13794,"date":"2003-07-23T00:00:00","date_gmt":"2003-07-23T00:00:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/uncategorized\/m006bmtg023\/"},"modified":"2019-03-01T15:05:30","modified_gmt":"2019-03-01T15:05:30","slug":"m006bmtg023","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/","title":{"rendered":"UNDERSTANDING OIG&#8217;S NEW COMPLIANCE PROGRAM"},"content":{"rendered":"<p>  <b>Featured Conference<\/b> <\/p>\n<p>    <a href=\"http:\/\/www.pharmedassociates.com\/regulatory.asp#p137\"><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/02\/pea-header.jpg\" width=\"393\" height=\"68\" border=\"0\" alt=\"Pharmaceutical Education Associates\"\/><\/a> <\/p>\n<p> <b><a href=\"http:\/\/www.pharmedassociates.com\/regulatory.asp#p137\">UNDERSTANDING OIG&#8217;S NEW COMPLIANCE PROGRAM GUIDANCE FOR PHARMACEUTICAL MANUFACTURERS &#8211; EXCLUSIVE ONE DAY SEMINAR<\/a><br \/> July 23, 2003 * The Westin Princeton at  Forrestal Village, Princeton, NJ<\/b> <\/p>\n<p>  <b>As a result of increased scrutiny, PhRMA issued their <i>Code on Interactions With Healthcare Professionals<\/i> in July, 2002,<\/b> in an effort to assist the Pharmaceutical Industry with some much needed perspective and guidance on its marketing, sales and promotional activities and what practices may raise a \u0093red flag\u0094 with both federal and state agencies. <b>Building upon the framework established by the <i>Code<\/i>, the Office of the Inspector General (OIG) issued a body of voluntary guidelines, <i>Compliance Program Guidance for Pharmaceutical Manufacturers<\/i><\/b>, to reinforce OIG\u0092s views on the fundamental elements of pharmaceutical manufacturer\u0092s compliance programs and principles that should be taken into account when creating and implementing an effective compliance program, as well as to serve as a benchmark for those companies with existing programs. With this publication, the Industry must now be proactive and diligent to maintain compliance in any of its public endeavors. <\/p>\n<p> Pharmaceutical Education Associates is proud to present, <b>OIG\u0092s New Compliance Program Guidance for Pharmaceutical Manufacturers: What <i>YOU<\/i> Need to Know<\/b>, an exclusive symposium that offers a comprehensive forum discussing and explaining what is currently expected by US governing and regulatory bodies. <\/p>\n<p> At this <b><i>first-ever forum<\/i><\/b>, hear from top experts in the country on topics including: <\/p>\n<ul>\n<li><b>Explaining the New Guidelines:  Key Areas of Potential Risk <\/b> <\/li>\n<li><b>The Effects of the New OIG Guidance on Common Marketing Practices for Pharmaceutical Manufacturers <\/b> <\/li>\n<li><b>Continuing Medical Education&#8217;s (CME) New Challenge:  The Office of the Inspector General<\/b> <\/li>\n<li><b>The Role Politics Played in the New OIG Definitions of Illegal Kickbacks and Other Remuneration<\/b> <\/li>\n<li><b>Medical Affairs and Publications: Getting the Message Right the Correct Way<\/b> <\/li>\n<li><b>Does Pharmaceutical Sponsorship Influence Science?  Approaches to Funding Scientific Communications in the Age of the OIG Guidance <\/b> <\/li>\n<li><b>Aligning with Pharmaceutical Benefit Managers (PBMs): Formularies and Formulary Support Activities<\/b> <\/li>\n<li><b>The Important Role of the Compliance Committee<\/b> <\/li>\n<li><b>Integrity of Data Used to Establish or Determine Government Reimbursement<\/b> <\/li>\n<li><b>The Role of Medical Affairs in Delivering Regulatory Guidelines for Product Promotion to a Sales Organization<\/b><\/li>\n<\/ul>\n<p><b>Hear From Our Faculty of Experts:<\/b> <\/p>\n<ul>\n<li><b>Cathy Young Thomer, Esq,<\/b> Special Assistant US Attorney, Eastern Division of Pennsylvania DEPARTMENT OF JUSTICE <\/li>\n<li><b>Matthew W. Davis, MD, RPh,<\/b> Vice President Clinical and Medical Affairs, DR. REDDY\u0092s LABORATORIES <\/li>\n<li><b>Mark H. Schaffer, EdM,<\/b> Vice President, Continuing Medical Education, THOMSON PROFESSIONAL POSTGRADUATE SERVICES\u00ae, a division of Thomson Physicians World <\/li>\n<li><b>John F. Kamp, Esq,<\/b> of Counsel, WILEY REIN &amp; FIELDING LLP   <\/li>\n<li><b>Steven James, MD, MBA,<\/b> Senior Director, Medical Affairs, ELAN PHARMACEUTICALS <\/li>\n<li><b>Lawrence E. Liberti, RPh, MSc, RAC,<\/b> President, PHARMACEUTICAL INFORMATION ASSOCIATES, LTD. <\/li>\n<li><b>W. David Dawson, PhD,<\/b> Global Head, Field Medical Affairs, Medical Information and          Science Director, EMD PHARMACEUTICALS, INC., an associate of MERCK KGAA,          Darmstadt, Germany<\/li>\n<\/ul>\n<p> Visit the conference site and register: <a href=\"http:\/\/www.pharmedassociates.com\/regulatory.asp#p137\">http:\/\/www.pharmedassociates.com\/regulatory.asp#p137<\/a> <\/p>\n<p> Also Call 800-280-8440 * Fax 831-465-2290 * Email <a href=\"mailto:tlewis@frallc.com\">tlewis@frallc.com<\/a> <\/p>\n<p>  <a href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/pm-mtgs.html\"><i>Return to list of conferences&#8230;<\/i><\/a> <\/p>\n<p\/>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical Education Associates presents Understanding the OIG&#8217;s Compliance Program Guidance for Pharmaceutical Manufacturers conference.<\/p>\n","protected":false},"author":2,"featured_media":13101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1203],"tags":[],"topic":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>UNDERSTANDING OIG&#039;S NEW COMPLIANCE PROGRAM - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UNDERSTANDING OIG&#039;S NEW COMPLIANCE PROGRAM - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"Pharmaceutical Education Associates presents Understanding the OIG&#039;s Compliance Program Guidance for Pharmaceutical Manufacturers conference.\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2003-07-23T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-03-01T15:05:30+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"744\" \/>\n\t<meta property=\"og:image:height\" content=\"419\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/\",\"name\":\"UNDERSTANDING OIG'S NEW COMPLIANCE PROGRAM - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2003-07-23T00:00:00+00:00\",\"dateModified\":\"2019-03-01T15:05:30+00:00\",\"author\":{\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UNDERSTANDING OIG&#8217;S NEW COMPLIANCE PROGRAM\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UNDERSTANDING OIG'S NEW COMPLIANCE PROGRAM - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/","og_locale":"en_US","og_type":"article","og_title":"UNDERSTANDING OIG'S NEW COMPLIANCE PROGRAM - Pharma Marketing Network","og_description":"Pharmaceutical Education Associates presents Understanding the OIG's Compliance Program Guidance for Pharmaceutical Manufacturers conference.","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/","og_site_name":"Pharma Marketing Network","article_published_time":"2003-07-23T00:00:00+00:00","article_modified_time":"2019-03-01T15:05:30+00:00","og_image":[{"width":744,"height":419,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/03\/pmn-logo-intro-post-1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/","name":"UNDERSTANDING OIG'S NEW COMPLIANCE PROGRAM - Pharma Marketing Network","isPartOf":{"@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2003-07-23T00:00:00+00:00","dateModified":"2019-03-01T15:05:30+00:00","author":{"@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/meetings\/m006bmtg023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"UNDERSTANDING OIG&#8217;S NEW COMPLIANCE PROGRAM"}]},{"@type":"WebSite","@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/13794"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=13794"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/13794\/revisions"}],"predecessor-version":[{"id":14022,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/13794\/revisions\/14022"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/13101"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=13794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=13794"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=13794"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=13794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}